Cyplasin-SC(TM) kills melanoma cells, even derived from different patients but leaves normal human cells unharmed


    EDMONTON, Sept. 5 /CNW/ - It is well known that many cancer types - or
even the same cancer in different patients - show different sensitivities to a
given therapeutic treatment. In earlier studies Cyplasin-SC(TM) has shown to
be an efficient killer of many cancer cell types whereas normal human cells
were left intact. An independent third party study conducted by Professor di
Liegro, Department of Medicine of the University of Palermo, Italy, tested
Cyplasin-SC(TM) on 5 melanoma cell lines derived from 5 different patients to
determine if all melanoma cells were equally susceptible to Cyplasin-SC(TM) or
if there were specific melanomas that did not respond to the drug. As a
control to these experiments normal human cells were also exposed to the same
concentrations of Cyplasin-SC(TM) used for the melanoma experiments.
    The results presented unequivocal evidence that all melanoma cell types
studied were killed by Cyplasin-SC(TM) whereas even at the highest
concentrations of Cyplasin-SC(TM) used in these experiments normal human cells
remained unaffected. However, within this group of five different human
melanomas, two were detected that required almost two times the dose that was
sufficient to kill other melanomas. This corresponds exactly to the situation
"in real life" where one patient reacts to low concentration of a given drug
whereas others require higher doses for the same therapeutic effect. Yet, even
such high doses were not harmful to normal human cells.
    These results confirm convincingly the usefulness of Cyplasin-SC(TM) as a
treatment of melanoma. The required concentrations for killing the individual
tumor can be efficiently optimized without harming normal cells, or in other
words, the concentration window for individual therapy is large and separated
enough from a concentration that may harm normal cells. These results will now
be transferred to animal dose ranging studies and continue on to actual
tumor-bearing animals.

    About Melanoma

    Market statistics for skin cancer and melanoma show that melanoma
currently affects more then 2.4 million people worldwide. In the US more than
62,000 new cases are reported every year, as fair-skinned and sunbelt
populations are at high risk for the disease. Australia has the highest rate
of melanoma in the world among males and has the second highest rate in the
world among females (Australia's Health 2004, AIHW). Overall the world wide
incidence has doubled over the past 20 years.

    About Cyplasin-SC(TM)

    Cyplasin-SC(TM) has demonstrated a selective ability to rapidly kill
certain types of cancer cells while leaving normal non-cancerous cells
untouched. Cyplasin-SC(TM) is a protein originally discovered and isolated by
Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The
protein can now be manufactured as a recombinant protein which allows the
company to develop the protein as a potential anti-cancer therapeutic product.
Patents have been issued to the Company covering the Cyplasin-SC(TM) protein.

    About Cyplasin Biomedical Ltd. (CBL)

    Founded in 2007 and headquartered in Edmonton, Canada with a research
laboratory close to Berlin, Germany, CBL is dedicated to bringing new
anticancer therapeutics to the marketplace. The Company's current goal is to
develop and commercialize the anticancer properties of Cyplasin-SC(TM). CBL is
publicly traded (CYPL:OTCBB)

For further information:

For further information: Garth Likes, President & CEO, Cyplasin
Biomedical Ltd., Direct phone (780) 469-CYPL(2975), FAX Number (780) 699-7933,
Website URL, Email Address

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890